- Home
- QNST vs NRIX Comparison
QNST vs NRIX Comparison
Compare QNST & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- NRIX
- Stock Information
- Founded
- QNST 1999
- NRIX 2009
- Country
- QNST United States
- NRIX United States
- Employees
- QNST N/A
- NRIX N/A
- Industry
- QNST Business Services
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- NRIX Health Care
- Exchange
- QNST Nasdaq
- NRIX Nasdaq
- Market Cap
- QNST 923.2M
- NRIX 750.4M
- IPO Year
- QNST 2010
- NRIX 2020
- Fundamental
- Price
- QNST $14.28
- NRIX $12.27
- Analyst Decision
- QNST Buy
- NRIX Strong Buy
- Analyst Count
- QNST 5
- NRIX 14
- Target Price
- QNST $26.40
- NRIX $26.29
- AVG Volume (30 Days)
- QNST 598.0K
- NRIX 1.9M
- Earning Date
- QNST 11-06-2025
- NRIX 10-09-2025
- Dividend Yield
- QNST N/A
- NRIX N/A
- EPS Growth
- QNST N/A
- NRIX N/A
- EPS
- QNST 0.18
- NRIX N/A
- Revenue
- QNST $1,100,345,000.00
- NRIX $83,687,000.00
- Revenue This Year
- QNST $11.18
- NRIX $58.48
- Revenue Next Year
- QNST $9.54
- NRIX N/A
- P/E Ratio
- QNST $80.43
- NRIX N/A
- Revenue Growth
- QNST 43.12
- NRIX 48.32
- 52 Week Low
- QNST $13.53
- NRIX $8.18
- 52 Week High
- QNST $25.50
- NRIX $28.20
- Technical
- Relative Strength Index (RSI)
- QNST 44.52
- NRIX 56.95
- Support Level
- QNST $13.53
- NRIX $12.01
- Resistance Level
- QNST $15.78
- NRIX $13.03
- Average True Range (ATR)
- QNST 0.66
- NRIX 0.84
- MACD
- QNST -0.00
- NRIX -0.02
- Stochastic Oscillator
- QNST 30.44
- NRIX 63.05
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.